The Food and Drug Administration on Monday approved Teva Pharmaceuticals' new treatment for Huntington's disease, a fatal degenerative disorder.
Here are three things to know.
1. Austedo is intended to treat chorea — an involuntary movement disorder — associated with Huntington's. Ninety percent of patients with the disease experience chorea.
2. The drug represents the second FDA-approved treatment for Huntington's.
3. Teva said the drug will be available in the next three weeks.
More articles on supply chain:
11 drugs on FDA's new safety alert list
How SSM Health's pharmacy concierge program helps patients manage high drug costs
Sanofi agrees to pay $20M for overcharging VA for vaccines: 4 things to know